,id,cid,dsn,cmpdname,srccmpd,srccmpdname,srccmpdurl,srctarget,srctargetname,srctargeturl,protacxn,protname,geneid,genename,taxid,taxname,action,actname,actvalue,evids,evurls,pmids,dois,citations
0,1134778,31357,Comparative Toxicogenomics Database (CTD),Tributyl phosphate,C009524,tributyl phosphate,https://ctdbase.org/detail.go?type=chem&acc=C009524,406936,MIR144,https://ctdbase.org/detail.go?type=gene&acc=406936,,,406936.0,MIR144,10090,Mus musculus (house mouse),Tributyl phosphate results in decreased expression of MIR144 mRNA,,,PMID:32105654,https://www.ncbi.nlm.nih.gov/pubmed/32105654,32105654.0,,
1,1156725,65411,Comparative Toxicogenomics Database (CTD),Triptonide,C084079,triptonide,https://ctdbase.org/detail.go?type=chem&acc=C084079,84901,NFATC2IP,https://ctdbase.org/detail.go?type=gene&acc=84901,,,84901.0,NFATC2IP,10090,Mus musculus (house mouse),Triptonide results in increased expression of NFATC2IP mRNA,,,PMID:33045310,https://www.ncbi.nlm.nih.gov/pubmed/33045310,33045310.0,,
2,1169352,222757,Comparative Toxicogenomics Database (CTD),Estradiol Benzoate,C074283,estradiol 3-benzoate,https://ctdbase.org/detail.go?type=chem&acc=C074283,16633,KLRA2,https://ctdbase.org/detail.go?type=gene&acc=16633,,,16633.0,Klra2,10116,Rattus norvegicus (Norway rat),[estradiol 3-benzoate co-treated with [testosterone co-treated with estradiol]] results in increased expression of KLRA2 mRNA,,,PMID:32741896,https://www.ncbi.nlm.nih.gov/pubmed/32741896,32741896.0,,
3,1169353,222757,Comparative Toxicogenomics Database (CTD),Estradiol Benzoate,C074283,estradiol 3-benzoate,https://ctdbase.org/detail.go?type=chem&acc=C074283,93969,KLRA22,https://ctdbase.org/detail.go?type=gene&acc=93969,,,93969.0,Klra22,10116,Rattus norvegicus (Norway rat),[estradiol 3-benzoate co-treated with [testosterone co-treated with estradiol]] results in increased expression of KLRA22 mRNA,,,PMID:32741896,https://www.ncbi.nlm.nih.gov/pubmed/32741896,32741896.0,,
4,1875559,9600409,Comparative Toxicogenomics Database (CTD),Citco,C475093,"6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime",https://ctdbase.org/detail.go?type=chem&acc=C475093,9970,NR1I3,https://ctdbase.org/detail.go?type=gene&acc=9970,,,9970.0,NR1I3,9719,Pusa sibirica (Baikal seal),"6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of NR1I3 mRNA",,,PMID:16929008,https://www.ncbi.nlm.nih.gov/pubmed/16929008,16929008.0,,
5,1969566,11519654,BindingDB,6-(4-Methanesulfonylphenyl)-5-({4-[2-(piperidin-1-yl)ethoxy]phenyl}methyl)naphthalen-2-ol,19965,6-(4-methanesulfonylphenyl)-5-({4-[2-(piperidin-1-yl)ethoxy]phenyl}methyl)naphthalen-2-ol,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19965,369,Estrogen receptor,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=369,P03372,Estrogen receptor,2099.0,ESR1,9606,Homo sapiens (human),,Ki (nM),1.15,PMID:16250633|DOI:10.1021/jm050723z,https://www.ncbi.nlm.nih.gov/pubmed/16250633|https://doi.org/10.1021/jm050723z,16250633.0,10.1021/jm050723z,
6,1969567,11519654,BindingDB,6-(4-Methanesulfonylphenyl)-5-({4-[2-(piperidin-1-yl)ethoxy]phenyl}methyl)naphthalen-2-ol,19965,6-(4-methanesulfonylphenyl)-5-({4-[2-(piperidin-1-yl)ethoxy]phenyl}methyl)naphthalen-2-ol,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=19965,370,Estrogen receptor beta,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=370,Q92731,Estrogen receptor beta,2100.0,ESR2,9606,Homo sapiens (human),,Ki (nM),24.1,PMID:16250633|DOI:10.1021/jm050723z,https://www.ncbi.nlm.nih.gov/pubmed/16250633|https://doi.org/10.1021/jm050723z,16250633.0,10.1021/jm050723z,
7,1969568,11519741,ChEMBL,Aclidinium Bromide,CHEMBL551466,ACLIDINIUM BROMIDE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL551466/,CHEMBL245,Muscarinic acetylcholine receptor M3,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL245/,P20309,Muscarinic acetylcholine receptor M3,1131.0,CHRM3,9606,Homo sapiens (human),Muscarinic acetylcholine receptor M3 antagonist,,,,,,,
8,1969569,11521821,Drug Gene Interaction database (DGIdb),Vabicaserin hydrochloride,,VABICASERIN HYDROCHLORIDE,https://www.dgidb.org/drugs/ncit:C142993,,HTR2B,https://www.dgidb.org/genes/hgnc:5294,,,3357.0,HTR2B,9606,Homo sapiens (human),Inhibitor,,,,,,,
9,1969570,11523212,BindingDB,tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-(naphthalen-2-yl)ethyl]carbamate,20113,"dipeptide-derived nitrile, 34",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=20113,2046,Procathepsin L,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2046,P25975,Procathepsin L,281108.0,CTSV,9913,Bos taurus (cattle),,Ki (nM),120,PMID:16302809|DOI:10.1021/jm050686b,https://www.ncbi.nlm.nih.gov/pubmed/16302809|https://doi.org/10.1021/jm050686b,16302809.0,10.1021/jm050686b,
10,1969571,11523212,BindingDB,tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-(naphthalen-2-yl)ethyl]carbamate,20113,"dipeptide-derived nitrile, 34",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=20113,2045,Papain,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=2045,P00784,Papain,,,3649,Carica papaya (papaya),,Ki (nM),21,PMID:16302809|DOI:10.1021/jm050686b,https://www.ncbi.nlm.nih.gov/pubmed/16302809|https://doi.org/10.1021/jm050686b,16302809.0,10.1021/jm050686b,
11,1969572,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,25800,SLC39A6,https://ctdbase.org/detail.go?type=gene&acc=25800,,,25800.0,SLC39A6,9606,Homo sapiens (human),"[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC39A6 mrna|[nog protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC39A6 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386.0,,
12,1969573,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,64116,SLC39A8,https://ctdbase.org/detail.go?type=gene&acc=64116,,,64116.0,SLC39A8,9606,Homo sapiens (human),"[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mrna|[nog protein co-treated with vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mrna|[nog protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mrna|[nog protein co-treated with panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mrna|[nog protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mrna|[nog protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC39A8 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386.0,,
13,1969584,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,6519,SLC3A1,https://ctdbase.org/detail.go?type=gene&acc=6519,,,6519.0,SLC3A1,9606,Homo sapiens (human),"[NOG protein co-treated with p-chloromercuribenzoic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC3A1 mrna|[nog protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC3A1 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386.0,,
14,1969585,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,6520,SLC3A2,https://ctdbase.org/detail.go?type=gene&acc=6520,,,6520.0,SLC3A2,9606,Homo sapiens (human),"[NOG protein co-treated with p-chloromercuribenzoic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC3A2 mrna|[nog protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC3A2 mrna|[nog protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC3A2 mrna|[nog protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC3A2 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386.0,,
15,1969586,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,796322,SLC3A2A,https://ctdbase.org/detail.go?type=gene&acc=796322,,,796322.0,slc3a2a,7955,Danio rerio (zebrafish),Dorsomorphin results in increased expression of SLC3A2A mRNA,,,PMID:30157643,https://www.ncbi.nlm.nih.gov/pubmed/30157643,30157643.0,,
16,1969587,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,30061,SLC40A1,https://ctdbase.org/detail.go?type=gene&acc=30061,,,30061.0,SLC40A1,9606,Homo sapiens (human),"[NOG protein co-treated with p-chloromercuribenzoic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mrna|[nog protein co-treated with phenylmercuric acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mrna|[nog protein co-treated with panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mrna|[nog protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mrna|[nog protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mrna|[nog protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC40A1 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386.0,,
17,1969588,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,8501,SLC43A1,https://ctdbase.org/detail.go?type=gene&acc=8501,,,8501.0,SLC43A1,9606,Homo sapiens (human),"[NOG protein co-treated with panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mrna|[nog protein co-treated with valproic acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mrna|[nog protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC43A1 mRNA",,,PMID:27188386,https://www.ncbi.nlm.nih.gov/pubmed/27188386,27188386.0,,
18,1969589,11524144,Comparative Toxicogenomics Database (CTD),Dorsomorphin,C516138,dorsomorphin,https://ctdbase.org/detail.go?type=chem&acc=C516138,494042,SLC43A2B,https://ctdbase.org/detail.go?type=gene&acc=494042,,,494042.0,slc43a2b,7955,Danio rerio (zebrafish),Dorsomorphin results in increased expression of SLC43A2B mRNA,,,PMID:30157643,https://www.ncbi.nlm.nih.gov/pubmed/30157643,30157643.0,,
19,1969293,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8292,COLQ,https://ctdbase.org/detail.go?type=gene&acc=8292,,,8292.0,COLQ,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of COLQ mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
20,1969294,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1363,CPE,https://ctdbase.org/detail.go?type=gene&acc=1363,,,1363.0,CPE,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CPE mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
21,1969295,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,283229,CRACR2B,https://ctdbase.org/detail.go?type=gene&acc=283229,,,283229.0,CRACR2B,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CRACR2B mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
22,1969296,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,90993,CREB3L1,https://ctdbase.org/detail.go?type=gene&acc=90993,,,90993.0,CREB3L1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CREB3L1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
23,1969297,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,84699,CREB3L3,https://ctdbase.org/detail.go?type=gene&acc=84699,,,84699.0,CREB3L3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CREB3L3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
24,1969298,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,200407,CREG2,https://ctdbase.org/detail.go?type=gene&acc=200407,,,200407.0,CREG2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CREG2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
25,1969299,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,202,CRYBG1,https://ctdbase.org/detail.go?type=gene&acc=202,,,202.0,CRYBG1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CRYBG1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
26,1969300,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1428,CRYM,https://ctdbase.org/detail.go?type=gene&acc=1428,,,1428.0,CRYM,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CRYM mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
27,1969301,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,51380,CSAD,https://ctdbase.org/detail.go?type=gene&acc=51380,,,51380.0,CSAD,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CSAD mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
28,1969302,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1440,CSF3,https://ctdbase.org/detail.go?type=gene&acc=1440,,,1440.0,CSF3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CSF3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
29,1969303,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1499,CTNNB1,https://ctdbase.org/detail.go?type=gene&acc=1499,,,1499.0,CTNNB1,10090,Mus musculus (house mouse),[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in decreased expression of CTNNB1 protein,,,PMID:37116855,https://www.ncbi.nlm.nih.gov/pubmed/37116855,37116855.0,,
30,1969304,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1075,CTSC,https://ctdbase.org/detail.go?type=gene&acc=1075,,,1075.0,CTSC,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CTSC mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
31,1969305,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1514,CTSL,https://ctdbase.org/detail.go?type=gene&acc=1514,,,1514.0,CTSL,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CTSL mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
32,1969306,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1519,CTSO,https://ctdbase.org/detail.go?type=gene&acc=1519,,,1519.0,CTSO,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CTSO mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
33,1969307,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,6376,CX3CL1,https://ctdbase.org/detail.go?type=gene&acc=6376,,,6376.0,CX3CL1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CX3CL1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
34,1969308,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3627,CXCL10,https://ctdbase.org/detail.go?type=gene&acc=3627,,,3627.0,CXCL10,10090,Mus musculus (house mouse),Trametinib promotes the reaction [lipopolysaccharides results in increased expression of CXCL10 mrna]|trametinib promotes the reaction [poly I-C results in increased expression of CXCL10 mrna],,,PMID:25780039,https://www.ncbi.nlm.nih.gov/pubmed/25780039,25780039.0,,
35,1969309,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,6374,CXCL5,https://ctdbase.org/detail.go?type=gene&acc=6374,,,6374.0,CXCL5,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CXCL5 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
36,1969310,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3576,CXCL8,https://ctdbase.org/detail.go?type=gene&acc=3576,,,3576.0,CXCL8,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CXCL8 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
37,1969311,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,56603,CYP26B1,https://ctdbase.org/detail.go?type=gene&acc=56603,,,56603.0,CYP26B1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CYP26B1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
38,1969312,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1556,CYP2B7P,https://ctdbase.org/detail.go?type=gene&acc=1556,,,1556.0,CYP2B7P,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CYP2B7P mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
39,1969313,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,171523,CYP2T1P,https://ctdbase.org/detail.go?type=gene&acc=171523,,,171523.0,CYP2T1P,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CYP2T1P mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
40,1969314,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,115265,DDIT4L,https://ctdbase.org/detail.go?type=gene&acc=115265,,,115265.0,DDIT4L,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DDIT4L mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
41,1969315,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,101929224,DDX59-AS1,https://ctdbase.org/detail.go?type=gene&acc=101929224,,,101929224.0,DDX59-AS1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DDX59-AS1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
42,1969323,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,55601,DDX60,https://ctdbase.org/detail.go?type=gene&acc=55601,,,55601.0,DDX60,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DDX60 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
43,1969324,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,22898,DENND3,https://ctdbase.org/detail.go?type=gene&acc=22898,,,22898.0,DENND3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DENND3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
44,1969325,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,11067,DEPP1,https://ctdbase.org/detail.go?type=gene&acc=11067,,,11067.0,DEPP1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DEPP1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
45,1969326,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,64798,DEPTOR,https://ctdbase.org/detail.go?type=gene&acc=64798,,,64798.0,DEPTOR,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DEPTOR mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
46,1969327,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,10202,DHRS2,https://ctdbase.org/detail.go?type=gene&acc=10202,,,10202.0,DHRS2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DHRS2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
47,1969328,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1734,DIO2,https://ctdbase.org/detail.go?type=gene&acc=1734,,,1734.0,DIO2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DIO2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
48,1969329,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,27122,DKK3,https://ctdbase.org/detail.go?type=gene&acc=27122,,,27122.0,DKK3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DKK3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
49,1969330,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,10395,DLC1,https://ctdbase.org/detail.go?type=gene&acc=10395,,,10395.0,DLC1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DLC1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
50,1969331,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8847,DLEU2,https://ctdbase.org/detail.go?type=gene&acc=8847,,,8847.0,DLEU2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DLEU2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
51,1969332,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,93099,DMKN,https://ctdbase.org/detail.go?type=gene&acc=93099,,,93099.0,DMKN,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DMKN mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
52,1969333,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,146562,DNAAF8,https://ctdbase.org/detail.go?type=gene&acc=146562,,,146562.0,DNAAF8,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DNAAF8 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
53,1969334,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8701,DNAH11,https://ctdbase.org/detail.go?type=gene&acc=8701,,,8701.0,DNAH11,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DNAH11 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
54,1969335,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8447,DOC2B,https://ctdbase.org/detail.go?type=gene&acc=8447,,,8447.0,DOC2B,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DOC2B mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
55,1969336,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,79930,DOK3,https://ctdbase.org/detail.go?type=gene&acc=79930,,,79930.0,DOK3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DOK3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
56,1969337,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,83450,DRC3,https://ctdbase.org/detail.go?type=gene&acc=83450,,,83450.0,DRC3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DRC3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
57,1969338,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,53905,DUOX1,https://ctdbase.org/detail.go?type=gene&acc=53905,,,53905.0,DUOX1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DUOX1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
58,1969339,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,50506,DUOX2,https://ctdbase.org/detail.go?type=gene&acc=50506,,,50506.0,DUOX2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUOX2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
59,1969340,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,90527,DUOXA1,https://ctdbase.org/detail.go?type=gene&acc=90527,,,90527.0,DUOXA1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUOXA1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
60,1969341,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1846,DUSP4,https://ctdbase.org/detail.go?type=gene&acc=1846,,,1846.0,DUSP4,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUSP4 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
61,1969342,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1847,DUSP5,https://ctdbase.org/detail.go?type=gene&acc=1847,,,1847.0,DUSP5,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUSP5 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
62,1969343,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1848,DUSP6,https://ctdbase.org/detail.go?type=gene&acc=1848,,,1848.0,DUSP6,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUSP6 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
63,1969344,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,106699570,DYNC1LI2-DT,https://ctdbase.org/detail.go?type=gene&acc=106699570,,,106699570.0,DYNC1LI2-DT,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DYNC1LI2-DT mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
64,1969345,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1870,E2F2,https://ctdbase.org/detail.go?type=gene&acc=1870,,,1870.0,E2F2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of E2F2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
65,1969346,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,144455,E2F7,https://ctdbase.org/detail.go?type=gene&acc=144455,,,144455.0,E2F7,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of E2F7 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
66,1969347,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,100506801,ECE1-AS1,https://ctdbase.org/detail.go?type=gene&acc=100506801,,,100506801.0,ECE1-AS1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ECE1-AS1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
67,1969348,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,30008,EFEMP2,https://ctdbase.org/detail.go?type=gene&acc=30008,,,30008.0,EFEMP2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EFEMP2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
68,1969349,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1944,EFNA3,https://ctdbase.org/detail.go?type=gene&acc=1944,,,1944.0,EFNA3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EFNA3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
69,1969350,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,1950,EGF,https://ctdbase.org/detail.go?type=gene&acc=1950,,,1950.0,EGF,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of EGF mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
70,1969351,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,317649,EIF4E3,https://ctdbase.org/detail.go?type=gene&acc=317649,,,317649.0,EIF4E3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EIF4E3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
71,1969352,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2001,ELF5,https://ctdbase.org/detail.go?type=gene&acc=2001,,,2001.0,ELF5,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ELF5 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
72,1969360,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,55531,ELMOD1,https://ctdbase.org/detail.go?type=gene&acc=55531,,,55531.0,ELMOD1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ELMOD1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
73,1969361,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2026,ENO2,https://ctdbase.org/detail.go?type=gene&acc=2026,,,2026.0,ENO2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ENO2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
74,1969362,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,387712,ENO4,https://ctdbase.org/detail.go?type=gene&acc=387712,,,387712.0,ENO4,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ENO4 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
75,1969363,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,5167,ENPP1,https://ctdbase.org/detail.go?type=gene&acc=5167,,,5167.0,ENPP1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ENPP1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
76,1969364,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,954,ENTPD2,https://ctdbase.org/detail.go?type=gene&acc=954,,,954.0,ENTPD2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ENTPD2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
77,1969365,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,100131434,EOLA1-DT,https://ctdbase.org/detail.go?type=gene&acc=100131434,,,100131434.0,EOLA1-DT,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of EOLA1-DT mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
78,1969366,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2034,EPAS1,https://ctdbase.org/detail.go?type=gene&acc=2034,,,2034.0,EPAS1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPAS1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
79,1969367,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2042,EPHA3,https://ctdbase.org/detail.go?type=gene&acc=2042,,,2042.0,EPHA3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPHA3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
80,1969368,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2046,EPHA8,https://ctdbase.org/detail.go?type=gene&acc=2046,,,2046.0,EPHA8,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPHA8 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
81,1969369,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,83481,EPPK1,https://ctdbase.org/detail.go?type=gene&acc=83481,,,83481.0,EPPK1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPPK1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
82,1969370,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,51752,ERAP1,https://ctdbase.org/detail.go?type=gene&acc=51752,,,51752.0,ERAP1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ERAP1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
83,1969371,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,64167,ERAP2,https://ctdbase.org/detail.go?type=gene&acc=64167,,,64167.0,ERAP2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ERAP2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
84,1969372,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,390937,ERFL,https://ctdbase.org/detail.go?type=gene&acc=390937,,,390937.0,ERFL,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ERFL mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
85,1969373,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,30001,ERO1A,https://ctdbase.org/detail.go?type=gene&acc=30001,,,30001.0,ERO1A,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ERO1A mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
86,1969374,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,54845,ESRP1,https://ctdbase.org/detail.go?type=gene&acc=54845,,,54845.0,ESRP1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ESRP1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
87,1969375,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2116,ETV2,https://ctdbase.org/detail.go?type=gene&acc=2116,,,2116.0,ETV2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ETV2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
88,1969376,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2118,ETV4,https://ctdbase.org/detail.go?type=gene&acc=2118,,,2118.0,ETV4,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ETV4 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
89,1969377,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2123,EVI2A,https://ctdbase.org/detail.go?type=gene&acc=2123,,,2123.0,EVI2A,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EVI2A mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
90,1969378,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,283673,EWSAT1,https://ctdbase.org/detail.go?type=gene&acc=283673,,,283673.0,EWSAT1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EWSAT1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
91,1969379,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,283849,EXOC3L1,https://ctdbase.org/detail.go?type=gene&acc=283849,,,283849.0,EXOC3L1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of EXOC3L1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
92,1969380,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,91828,EXOC3L4,https://ctdbase.org/detail.go?type=gene&acc=91828,,,91828.0,EXOC3L4,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of EXOC3L4 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
93,1969381,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,23086,EXPH5,https://ctdbase.org/detail.go?type=gene&acc=23086,,,23086.0,EXPH5,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EXPH5 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
94,1969382,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2150,F2RL1,https://ctdbase.org/detail.go?type=gene&acc=2150,,,2150.0,F2RL1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of F2RL1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
95,1969383,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,83641,FAM107B,https://ctdbase.org/detail.go?type=gene&acc=83641,,,83641.0,FAM107B,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FAM107B mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
96,1969384,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,374393,FAM111B,https://ctdbase.org/detail.go?type=gene&acc=374393,,,374393.0,FAM111B,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FAM111B mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
97,1969385,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,84070,FAM186B,https://ctdbase.org/detail.go?type=gene&acc=84070,,,84070.0,FAM186B,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FAM186B mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
98,1969386,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,132720,FAM241A,https://ctdbase.org/detail.go?type=gene&acc=132720,,,132720.0,FAM241A,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FAM241A mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
99,1969387,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2194,FASN,https://ctdbase.org/detail.go?type=gene&acc=2194,,,2194.0,FASN,9606,Homo sapiens (human),Trametinib affects the reaction [[BRAF protein affects the susceptibility to vemurafenib] which affects the expression of FASN mrna],,,PMID:29950559,https://www.ncbi.nlm.nih.gov/pubmed/29950559,29950559.0,,
100,1969388,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2196,FAT2,https://ctdbase.org/detail.go?type=gene&acc=2196,,,2196.0,FAT2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FAT2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
101,1969389,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,89885,FATE1,https://ctdbase.org/detail.go?type=gene&acc=89885,,,89885.0,FATE1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FATE1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
102,1969397,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,130888,FBXO36,https://ctdbase.org/detail.go?type=gene&acc=130888,,,130888.0,FBXO36,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FBXO36 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
103,1969398,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2232,FDXR,https://ctdbase.org/detail.go?type=gene&acc=2232,,,2232.0,FDXR,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FDXR mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
104,1969399,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,9965,FGF19,https://ctdbase.org/detail.go?type=gene&acc=9965,,,9965.0,FGF19,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FGF19 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
105,1969400,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,729830,FHIP1A,https://ctdbase.org/detail.go?type=gene&acc=729830,,,729830.0,FHIP1A,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FHIP1A mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
106,1969401,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,286467,FIRRE,https://ctdbase.org/detail.go?type=gene&acc=286467,,,286467.0,FIRRE,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FIRRE mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
107,1969402,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,642489,FKBP1C,https://ctdbase.org/detail.go?type=gene&acc=642489,,,642489.0,FKBP1C,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FKBP1C mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
108,1969403,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,130540,FLACC1,https://ctdbase.org/detail.go?type=gene&acc=130540,,,130540.0,FLACC1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FLACC1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
109,1969404,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2318,FLNC,https://ctdbase.org/detail.go?type=gene&acc=2318,,,2318.0,FLNC,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FLNC mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
110,1969405,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,342184,FMN1,https://ctdbase.org/detail.go?type=gene&acc=342184,,,342184.0,FMN1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FMN1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
111,1969406,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,79025,FNDC11,https://ctdbase.org/detail.go?type=gene&acc=79025,,,79025.0,FNDC11,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FNDC11 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
112,1969415,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2298,FOXD4,https://ctdbase.org/detail.go?type=gene&acc=2298,,,2298.0,FOXD4,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FOXD4 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
113,1969416,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,94234,FOXQ1,https://ctdbase.org/detail.go?type=gene&acc=94234,,,94234.0,FOXQ1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FOXQ1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
114,1969417,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,100526835,FPGT-TNNI3K,https://ctdbase.org/detail.go?type=gene&acc=100526835,,,100526835.0,FPGT-TNNI3K,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FPGT-TNNI3K mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
115,1969418,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,23150,FRMD4B,https://ctdbase.org/detail.go?type=gene&acc=23150,,,23150.0,FRMD4B,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FRMD4B mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
116,1969419,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,6624,FSCN1,https://ctdbase.org/detail.go?type=gene&acc=6624,,,6624.0,FSCN1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FSCN1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
117,1969420,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,170384,FUT11,https://ctdbase.org/detail.go?type=gene&acc=170384,,,170384.0,FUT11,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FUT11 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
118,1969421,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,199920,FYB2,https://ctdbase.org/detail.go?type=gene&acc=199920,,,199920.0,FYB2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FYB2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
119,1969422,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,9846,GAB2,https://ctdbase.org/detail.go?type=gene&acc=9846,,,9846.0,GAB2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GAB2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
120,1969423,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2571,GAD1,https://ctdbase.org/detail.go?type=gene&acc=2571,,,2571.0,GAD1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GAD1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
121,1969424,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,9514,GAL3ST1,https://ctdbase.org/detail.go?type=gene&acc=9514,,,9514.0,GAL3ST1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GAL3ST1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
122,1969432,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,51809,GALNT7,https://ctdbase.org/detail.go?type=gene&acc=51809,,,51809.0,GALNT7,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GALNT7 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
123,1969433,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2621,GAS6,https://ctdbase.org/detail.go?type=gene&acc=2621,,,2621.0,GAS6,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GAS6 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
124,1969434,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,100506394,GAS6-DT,https://ctdbase.org/detail.go?type=gene&acc=100506394,,,100506394.0,GAS6-DT,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GAS6-DT mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
125,1969446,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2731,GLDC,https://ctdbase.org/detail.go?type=gene&acc=2731,,,2731.0,GLDC,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GLDC mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
126,1969447,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2752,GLUL,https://ctdbase.org/detail.go?type=gene&acc=2752,,,2752.0,GLUL,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GLUL mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
127,1969448,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2767,GNA11,https://ctdbase.org/detail.go?type=gene&acc=2767,,,2767.0,GNA11,9606,Homo sapiens (human),GNA11 protein mutant form results in increased susceptibility to trametinib,,,PMID:22733540,https://www.ncbi.nlm.nih.gov/pubmed/22733540,22733540.0,,
128,1969449,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2776,GNAQ,https://ctdbase.org/detail.go?type=gene&acc=2776,,,2776.0,GNAQ,9606,Homo sapiens (human),GNAQ gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]|[gnaq gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP7 protein|gnaq protein mutant form results in increased susceptibility to trametinib|[gnaq gene mutant form results in increased susceptibility to [trametinib co-treated with omipalisib]] which results in increased cleavage of CASP3 protein,,,PMID:22733540,https://www.ncbi.nlm.nih.gov/pubmed/22733540,22733540.0,,
129,1969450,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,10457,GPNMB,https://ctdbase.org/detail.go?type=gene&acc=10457,,,10457.0,GPNMB,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GPNMB mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
130,1969451,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,115330,GPR146,https://ctdbase.org/detail.go?type=gene&acc=115330,,,115330.0,GPR146,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GPR146 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
131,1969459,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,9283,GPR37L1,https://ctdbase.org/detail.go?type=gene&acc=9283,,,9283.0,GPR37L1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GPR37L1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
132,1969460,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2863,GPR39,https://ctdbase.org/detail.go?type=gene&acc=2863,,,2863.0,GPR39,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GPR39 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
133,1969461,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,53836,GPR87,https://ctdbase.org/detail.go?type=gene&acc=53836,,,53836.0,GPR87,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GPR87 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
134,1969462,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,57476,GRAMD1B,https://ctdbase.org/detail.go?type=gene&acc=57476,,,57476.0,GRAMD1B,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GRAMD1B mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
135,1969463,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2886,GRB7,https://ctdbase.org/detail.go?type=gene&acc=2886,,,2886.0,GRB7,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GRB7 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
136,1969464,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2906,GRIN2D,https://ctdbase.org/detail.go?type=gene&acc=2906,,,2906.0,GRIN2D,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GRIN2D mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
137,1969465,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,56169,GSDMC,https://ctdbase.org/detail.go?type=gene&acc=56169,,,56169.0,GSDMC,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GSDMC mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
138,1969466,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2932,GSK3B,https://ctdbase.org/detail.go?type=gene&acc=2932,,,2932.0,GSK3B,10090,Mus musculus (house mouse),[trametinib co-treated with 6-bromoindirubin-3'-oxime] affects the phosphorylation of GSK3B protein,,,PMID:37116855,https://www.ncbi.nlm.nih.gov/pubmed/37116855,37116855.0,,
139,1969467,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,84163,GTF2IRD2,https://ctdbase.org/detail.go?type=gene&acc=84163,,,84163.0,GTF2IRD2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GTF2IRD2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
140,1969468,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,2979,GUCA1B,https://ctdbase.org/detail.go?type=gene&acc=2979,,,2979.0,GUCA1B,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GUCA1B mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
141,1969469,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3006,H1-2,https://ctdbase.org/detail.go?type=gene&acc=3006,,,3006.0,H1-2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H1-2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
142,1969470,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8969,H2AC11,https://ctdbase.org/detail.go?type=gene&acc=8969,,,8969.0,H2AC11,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H2AC11 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
143,1969471,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8329,H2AC13,https://ctdbase.org/detail.go?type=gene&acc=8329,,,8329.0,H2AC13,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H2AC13 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
144,1969472,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8334,H2AC6,https://ctdbase.org/detail.go?type=gene&acc=8334,,,8334.0,H2AC6,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H2AC6 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
145,1969473,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8357,H3C10,https://ctdbase.org/detail.go?type=gene&acc=8357,,,8357.0,H3C10,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H3C10 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
146,1969474,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8358,H3C2,https://ctdbase.org/detail.go?type=gene&acc=8358,,,8358.0,H3C2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H3C2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
147,1969475,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8370,H4C14,https://ctdbase.org/detail.go?type=gene&acc=8370,,,8370.0,H4C14,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H4C14 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
148,1969476,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8365,H4C8,https://ctdbase.org/detail.go?type=gene&acc=8365,,,8365.0,H4C8,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H4C8 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
149,1969477,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3034,HAL,https://ctdbase.org/detail.go?type=gene&acc=3034,,,3034.0,HAL,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HAL mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
150,1969488,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3099,HK2,https://ctdbase.org/detail.go?type=gene&acc=3099,,,3099.0,HK2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HK2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
151,1969489,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,80201,HKDC1,https://ctdbase.org/detail.go?type=gene&acc=80201,,,80201.0,HKDC1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HKDC1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
152,1969490,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3113,HLA-DPA1,https://ctdbase.org/detail.go?type=gene&acc=3113,,,3113.0,HLA-DPA1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HLA-DPA1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
153,1969491,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,112817,HOGA1,https://ctdbase.org/detail.go?type=gene&acc=112817,,,112817.0,HOGA1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HOGA1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
154,1969492,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3209,HOXA13,https://ctdbase.org/detail.go?type=gene&acc=3209,,,3209.0,HOXA13,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HOXA13 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
155,1969493,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3219,HOXB9,https://ctdbase.org/detail.go?type=gene&acc=3219,,,3219.0,HOXB9,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HOXB9 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
156,1969494,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3221,HOXC4,https://ctdbase.org/detail.go?type=gene&acc=3221,,,3221.0,HOXC4,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HOXC4 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
157,1969495,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,51440,HPCAL4,https://ctdbase.org/detail.go?type=gene&acc=51440,,,51440.0,HPCAL4,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HPCAL4 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
158,1969496,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,9953,HS3ST3B1,https://ctdbase.org/detail.go?type=gene&acc=9953,,,9953.0,HS3ST3B1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HS3ST3B1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
159,1969497,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,51171,HSD17B14,https://ctdbase.org/detail.go?type=gene&acc=51171,,,51171.0,HSD17B14,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HSD17B14 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
160,1969498,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3303,HSPA1A,https://ctdbase.org/detail.go?type=gene&acc=3303,,,3303.0,HSPA1A,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HSPA1A mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
161,1969509,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3570,IL6R,https://ctdbase.org/detail.go?type=gene&acc=3570,,,3570.0,IL6R,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IL6R mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
162,1969510,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,389119,INKA1,https://ctdbase.org/detail.go?type=gene&acc=389119,,,389119.0,INKA1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of INKA1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
163,1969511,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3635,INPP5D,https://ctdbase.org/detail.go?type=gene&acc=3635,,,3635.0,INPP5D,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of INPP5D mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
164,1969512,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,388135,INSYN1,https://ctdbase.org/detail.go?type=gene&acc=388135,,,388135.0,INSYN1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of INSYN1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
165,1969513,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,642574,IQANK1,https://ctdbase.org/detail.go?type=gene&acc=642574,,,642574.0,IQANK1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IQANK1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
166,1969514,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,80726,IQCN,https://ctdbase.org/detail.go?type=gene&acc=80726,,,80726.0,IQCN,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of IQCN mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
167,1969515,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3656,IRAK2,https://ctdbase.org/detail.go?type=gene&acc=3656,,,3656.0,IRAK2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IRAK2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
168,1969516,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3659,IRF1,https://ctdbase.org/detail.go?type=gene&acc=3659,,,3659.0,IRF1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of IRF1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
169,1969517,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3661,IRF3,https://ctdbase.org/detail.go?type=gene&acc=3661,,,3661.0,IRF3,10090,Mus musculus (house mouse),Trametinib promotes the reaction [lipopolysaccharides results in increased phosphorylation of IRF3 protein],,,PMID:25780039,https://www.ncbi.nlm.nih.gov/pubmed/25780039,25780039.0,,
170,1969518,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,145501,ISM2,https://ctdbase.org/detail.go?type=gene&acc=145501,,,145501.0,ISM2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ISM2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
171,1969519,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,8515,ITGA10,https://ctdbase.org/detail.go?type=gene&acc=8515,,,8515.0,ITGA10,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGA10 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
172,1969520,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3673,ITGA2,https://ctdbase.org/detail.go?type=gene&acc=3673,,,3673.0,ITGA2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGA2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
173,1969521,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3655,ITGA6,https://ctdbase.org/detail.go?type=gene&acc=3655,,,3655.0,ITGA6,9606,Homo sapiens (human),XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of ITGA6 protein]|[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of ITGA6 protein,,,PMID:37116855,https://www.ncbi.nlm.nih.gov/pubmed/37116855,37116855.0,,
174,1969522,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3687,ITGAX,https://ctdbase.org/detail.go?type=gene&acc=3687,,,3687.0,ITGAX,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGAX mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
175,1969523,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3690,ITGB3,https://ctdbase.org/detail.go?type=gene&acc=3690,,,3690.0,ITGB3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGB3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
176,1969524,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3691,ITGB4,https://ctdbase.org/detail.go?type=gene&acc=3691,,,3691.0,ITGB4,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGB4 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
177,1969525,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,101927811,ITGB8-AS1,https://ctdbase.org/detail.go?type=gene&acc=101927811,,,101927811.0,ITGB8-AS1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGB8-AS1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
178,1969526,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3718,JAK3,https://ctdbase.org/detail.go?type=gene&acc=3718,,,3718.0,JAK3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of JAK3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
179,1969527,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,58494,JAM2,https://ctdbase.org/detail.go?type=gene&acc=58494,,,58494.0,JAM2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of JAM2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
180,1969528,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3725,JUN,https://ctdbase.org/detail.go?type=gene&acc=3725,,,3725.0,JUN,9606,Homo sapiens (human),JUN results in decreased susceptibility to [omipalisib co-treated with trametinib]|[omipalisib co-treated with trametinib] results in increased phosphorylation of JUN protein,,,PMID:22733540,https://www.ncbi.nlm.nih.gov/pubmed/22733540,22733540.0,,
181,1969538,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3872,KRT17,https://ctdbase.org/detail.go?type=gene&acc=3872,,,3872.0,KRT17,9606,Homo sapiens (human),XAV939 inhibits the reaction [[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of KRT17 protein]|[trametinib co-treated with 6-bromoindirubin-3'-oxime] results in increased expression of KRT17 protein,,,PMID:37116855,https://www.ncbi.nlm.nih.gov/pubmed/37116855,37116855.0,,
182,1969539,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3855,KRT7,https://ctdbase.org/detail.go?type=gene&acc=3855,,,3855.0,KRT7,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KRT7 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
183,1969540,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3892,KRT86,https://ctdbase.org/detail.go?type=gene&acc=3892,,,3892.0,KRT86,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KRT86 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
184,1969541,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3898,LAD1,https://ctdbase.org/detail.go?type=gene&acc=3898,,,3898.0,LAD1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAD1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
185,1969542,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3908,LAMA2,https://ctdbase.org/detail.go?type=gene&acc=3908,,,3908.0,LAMA2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAMA2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
186,1969543,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3910,LAMA4,https://ctdbase.org/detail.go?type=gene&acc=3910,,,3910.0,LAMA4,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAMA4 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
187,1969544,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3918,LAMC2,https://ctdbase.org/detail.go?type=gene&acc=3918,,,3918.0,LAMC2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAMC2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
188,1969545,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,7805,LAPTM5,https://ctdbase.org/detail.go?type=gene&acc=7805,,,7805.0,LAPTM5,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LAPTM5 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
189,1969546,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,105376382,LASTR,https://ctdbase.org/detail.go?type=gene&acc=105376382,,,105376382.0,LASTR,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LASTR mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
190,1969547,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,7462,LAT2,https://ctdbase.org/detail.go?type=gene&acc=7462,,,7462.0,LAT2,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LAT2 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
191,1969548,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3936,LCP1,https://ctdbase.org/detail.go?type=gene&acc=3936,,,3936.0,LCP1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LCP1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
192,1969549,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3949,LDLR,https://ctdbase.org/detail.go?type=gene&acc=3949,,,3949.0,LDLR,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LDLR mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
193,1969550,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,388633,LDLRAD1,https://ctdbase.org/detail.go?type=gene&acc=388633,,,388633.0,LDLRAD1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LDLRAD1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
194,1969551,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,753,LDLRAD4,https://ctdbase.org/detail.go?type=gene&acc=753,,,753.0,LDLRAD4,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LDLRAD4 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
195,1969552,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,93273,LEMD1,https://ctdbase.org/detail.go?type=gene&acc=93273,,,93273.0,LEMD1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LEMD1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
196,1969553,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3965,LGALS9,https://ctdbase.org/detail.go?type=gene&acc=3965,,,3965.0,LGALS9,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LGALS9 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
197,1969554,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,203190,LGI3,https://ctdbase.org/detail.go?type=gene&acc=203190,,,203190.0,LGI3,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LGI3 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
198,1969555,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,3975,LHX1,https://ctdbase.org/detail.go?type=gene&acc=3975,,,3975.0,LHX1,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LHX1 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
199,1969556,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,26468,LHX6,https://ctdbase.org/detail.go?type=gene&acc=26468,,,26468.0,LHX6,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LHX6 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
200,1969557,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,751580,LINC00106,https://ctdbase.org/detail.go?type=gene&acc=751580,,,751580.0,LINC00106,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC00106 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
201,1969558,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,100846978,LINC00506,https://ctdbase.org/detail.go?type=gene&acc=100846978,,,100846978.0,LINC00506,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC00506 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
202,1969574,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,149837,LINC00654,https://ctdbase.org/detail.go?type=gene&acc=149837,,,149837.0,LINC00654,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LINC00654 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
203,1969575,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,100652730,LINC00659,https://ctdbase.org/detail.go?type=gene&acc=100652730,,,100652730.0,LINC00659,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LINC00659 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
204,1969576,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,106660612,LINC00680,https://ctdbase.org/detail.go?type=gene&acc=106660612,,,106660612.0,LINC00680,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC00680 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
205,1969577,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,100507127,LINC00707,https://ctdbase.org/detail.go?type=gene&acc=100507127,,,100507127.0,LINC00707,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LINC00707 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
206,1969578,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,100131551,LINC00887,https://ctdbase.org/detail.go?type=gene&acc=100131551,,,100131551.0,LINC00887,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LINC00887 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
207,1969579,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,100506810,LINC01132,https://ctdbase.org/detail.go?type=gene&acc=100506810,,,100506810.0,LINC01132,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC01132 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
208,1969580,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,100996702,LINC01356,https://ctdbase.org/detail.go?type=gene&acc=100996702,,,100996702.0,LINC01356,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LINC01356 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
209,1969581,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,400685,LINC01801,https://ctdbase.org/detail.go?type=gene&acc=400685,,,400685.0,LINC01801,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC01801 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
210,1969582,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,101926975,LINC01844,https://ctdbase.org/detail.go?type=gene&acc=101926975,,,101926975.0,LINC01844,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LINC01844 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
211,1969583,11707110,Comparative Toxicogenomics Database (CTD),Trametinib,C560077,trametinib,https://ctdbase.org/detail.go?type=chem&acc=C560077,107984773,LINC01852,https://ctdbase.org/detail.go?type=gene&acc=107984773,,,107984773.0,LINC01852,9606,Homo sapiens (human),[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LINC01852 mRNA,,,PMID:36139627,https://www.ncbi.nlm.nih.gov/pubmed/36139627,36139627.0,,
212,1969316,11845584,BindingDB,"(2R,4S)-4-[(4aS,12R,15S,17aR)-15-methyl-14,17-dioxo-1H,2H,3H,4H,4aH,5H,6H,9H,11H,12H,13H,14H,15H,16H,17H,17aH-pyrido[2,3-i][,,]cyclopentadecan-12-yl]-N-butyl-4-hydroxy-2-methylbutanamide",16092,"(2R,4S)-4-[(4aS,12R,15S,17aR)-15-methyl-14,17-dioxo-1H,2H,3H,4H,4aH,5H,6H,9H,11H,12H,13H,14H,15H,16H,17H,17aH-pyrido[2,3-i][,,]cyclopentadecan-12-yl]-N-butyl-4-hydroxy-2-methylbutanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16092,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),>10000,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
213,1969317,11845584,BindingDB,"(2R,4S)-4-[(4aS,12R,15S,17aR)-15-methyl-14,17-dioxo-1H,2H,3H,4H,4aH,5H,6H,9H,11H,12H,13H,14H,15H,16H,17H,17aH-pyrido[2,3-i][,,]cyclopentadecan-12-yl]-N-butyl-4-hydroxy-2-methylbutanamide",16092,"(2R,4S)-4-[(4aS,12R,15S,17aR)-15-methyl-14,17-dioxo-1H,2H,3H,4H,4aH,5H,6H,9H,11H,12H,13H,14H,15H,16H,17H,17aH-pyrido[2,3-i][,,]cyclopentadecan-12-yl]-N-butyl-4-hydroxy-2-methylbutanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16092,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),6900,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
214,1969318,11846124,BindingDB,"2-Pyridinecarboxamide, 4-amino-5-cyano-6-ethoxy-N-[[4-(methylsulfonyl)phenyl]methyl]-",15913,2-pyridinecarboxamide deriv. 8c,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15913,1663,Mitogen-activated protein kinase 9,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1663,P45984,Mitogen-activated protein kinase 9,5601.0,MAPK9,9606,Homo sapiens (human),,IC50 (nM),120,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
215,1969321,11846124,BindingDB,"2-Pyridinecarboxamide, 4-amino-5-cyano-6-ethoxy-N-[[4-(methylsulfonyl)phenyl]methyl]-",15913,2-pyridinecarboxamide deriv. 8c,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15913,1662,Mitogen-activated protein kinase 8,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1662,P45983,Mitogen-activated protein kinase 8,5599.0,MAPK8,9606,Homo sapiens (human),,IC50 (nM),19,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
216,1969322,11846125,BindingDB,4-amino-5-cyano-6-ethoxy-N-[(2-sulfamoylphenyl)methyl]pyridine-2-carboxamide,15914,2-pyridinecarboxamide deriv. 8d,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15914,1662,Mitogen-activated protein kinase 8,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1662,P45983,Mitogen-activated protein kinase 8,5599.0,MAPK8,9606,Homo sapiens (human),,IC50 (nM),12,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
217,1969353,11846125,BindingDB,4-amino-5-cyano-6-ethoxy-N-[(2-sulfamoylphenyl)methyl]pyridine-2-carboxamide,15914,2-pyridinecarboxamide deriv. 8d,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15914,1663,Mitogen-activated protein kinase 9,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1663,P45984,Mitogen-activated protein kinase 9,5601.0,MAPK9,9606,Homo sapiens (human),,IC50 (nM),53,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
218,1969319,11846126,BindingDB,4-amino-5-cyano-6-ethoxy-N-(pyridin-3-ylmethyl)pyridine-2-carboxamide,15915,2-pyridinecarboxamide deriv. 8e,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15915,1662,Mitogen-activated protein kinase 8,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1662,P45983,Mitogen-activated protein kinase 8,5599.0,MAPK8,9606,Homo sapiens (human),,IC50 (nM),26,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
219,1969320,11846126,BindingDB,4-amino-5-cyano-6-ethoxy-N-(pyridin-3-ylmethyl)pyridine-2-carboxamide,15915,2-pyridinecarboxamide deriv. 8e,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15915,1663,Mitogen-activated protein kinase 9,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1663,P45984,Mitogen-activated protein kinase 9,5601.0,MAPK9,9606,Homo sapiens (human),,IC50 (nM),41,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
220,1969354,11846138,BindingDB,"tert-butyl N-[(3S,6S,9S,13Z)-3-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1,11-dioxa-4,7-diazacyclopentadec-13-en-9-yl]carbamate",16080,Olefins were mixtures of cis and trans isomers.,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16080,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),910,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
221,1969355,11846138,BindingDB,"tert-butyl N-[(3S,6S,9S,13Z)-3-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1,11-dioxa-4,7-diazacyclopentadec-13-en-9-yl]carbamate",16080,Olefins were mixtures of cis and trans isomers.,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16080,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),20300,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
222,1969356,11846139,BindingDB,"tert-butyl N-[(3S,6S,9R,13Z)-3-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1-oxa-11-thia-4,7-diazacyclopentadec-13-en-9-yl]carbamate",16081,Olefins were mixtures of cis and trans isomers.,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16081,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),510,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
223,1969357,11846139,BindingDB,"tert-butyl N-[(3S,6S,9R,13Z)-3-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1-oxa-11-thia-4,7-diazacyclopentadec-13-en-9-yl]carbamate",16081,Olefins were mixtures of cis and trans isomers.,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16081,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),110,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
224,1969358,11846287,BindingDB,4-(5-{[(4-Amino-5-cyano-6-ethoxypyridin-2-yl)formamido]methyl}pyridin-2-yl)benzoic acid,15916,2-pyridinecarboxamide deriv. 8f,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15916,1663,Mitogen-activated protein kinase 9,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1663,P45984,Mitogen-activated protein kinase 9,5601.0,MAPK9,9606,Homo sapiens (human),,IC50 (nM),11,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
225,1969392,11846287,BindingDB,4-(5-{[(4-Amino-5-cyano-6-ethoxypyridin-2-yl)formamido]methyl}pyridin-2-yl)benzoic acid,15916,2-pyridinecarboxamide deriv. 8f,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15916,1662,Mitogen-activated protein kinase 8,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1662,P45983,Mitogen-activated protein kinase 8,5599.0,MAPK8,9606,Homo sapiens (human),,IC50 (nM),4,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
226,1969393,11846288,BindingDB,2-Pyridinecarboxamide deriv. 8g,15917,2-pyridinecarboxamide deriv. 8g,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15917,1662,Mitogen-activated protein kinase 8,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1662,P45983,Mitogen-activated protein kinase 8,5599.0,MAPK8,9606,Homo sapiens (human),,IC50 (nM),6400,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
227,1969394,11846288,BindingDB,2-Pyridinecarboxamide deriv. 8g,15917,2-pyridinecarboxamide deriv. 8g,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15917,1663,Mitogen-activated protein kinase 9,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1663,P45984,Mitogen-activated protein kinase 9,5601.0,MAPK9,9606,Homo sapiens (human),,IC50 (nM),>10000,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
228,1969359,11846294,BindingDB,5-Cyano-6-ethoxy-pyridine-2-carboxylic acid 4-methanesulfonyl-benzylamide,15921,2-pyridinecarboxamide deriv. 17a,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15921,1662,Mitogen-activated protein kinase 8,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1662,P45983,Mitogen-activated protein kinase 8,5599.0,MAPK8,9606,Homo sapiens (human),,IC50 (nM),390,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
229,1969390,11846301,BindingDB,"(2R,4S)-4-[(3S,6S,9R,13Z)-9-(acetylamino)-6-methyl-5,8-dioxo-1-oxa-11-thia-4,7-diazacyclopentadec-13-en-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",16082,"(2R,4S)-4-[(3S,6S,9R,13Z)-9-(acetylamino)-6-methyl-5,8-dioxo-1-oxa-11-thia-4,7-diazacyclopentadec-13-en-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16082,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),6000,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
230,1969391,11846301,BindingDB,"(2R,4S)-4-[(3S,6S,9R,13Z)-9-(acetylamino)-6-methyl-5,8-dioxo-1-oxa-11-thia-4,7-diazacyclopentadec-13-en-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",16082,"(2R,4S)-4-[(3S,6S,9R,13Z)-9-(acetylamino)-6-methyl-5,8-dioxo-1-oxa-11-thia-4,7-diazacyclopentadec-13-en-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16082,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),1120,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
231,1969395,11846304,BindingDB,"tert-butyl N-[(3R,6S,9R)-3-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadecan-9-yl]carbamate",16064,dithia macrocycle compound 23,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16064,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),180,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
232,1969453,11846304,BindingDB,"tert-butyl N-[(3R,6S,9R)-3-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadecan-9-yl]carbamate",16064,dithia macrocycle compound 23,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16064,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),20000,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
233,1969454,11846305,BindingDB,"tert-butyl N-[(3R,6S,9R)-3-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclohexadecan-9-yl]carbamate",16065,dithia macrocycle compound 24,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16065,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),16900,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
234,1969457,11846305,BindingDB,"tert-butyl N-[(3R,6S,9R)-3-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclohexadecan-9-yl]carbamate",16065,dithia macrocycle compound 24,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16065,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),20,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
235,1969396,11846306,BindingDB,"tert-butyl N-[(5R,8S,11R)-5-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-8-methyl-7,10-dioxo-3,13-dithia-6,9-diazabicyclo[13.2.2]nonadeca-1(17),15,18-trien-11-yl]carbamate",16067,dithia macrocycle compound 26,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16067,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),195,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
236,1969407,11846306,BindingDB,"tert-butyl N-[(5R,8S,11R)-5-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-8-methyl-7,10-dioxo-3,13-dithia-6,9-diazabicyclo[13.2.2]nonadeca-1(17),15,18-trien-11-yl]carbamate",16067,dithia macrocycle compound 26,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16067,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),>10000,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
237,1969408,11846457,BindingDB,"4-Amino-6-(2,5-dimethoxy-benzylamino)-2-ethoxy-nicotinonitrile",15910,"4-Amino-6-(2,5-dimethoxy-benzylamino)-2-ethoxy-nicotinonitrile",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15910,1662,Mitogen-activated protein kinase 8,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1662,P45983,Mitogen-activated protein kinase 8,5599.0,MAPK8,9606,Homo sapiens (human),,IC50 (nM),>10000,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
238,1969409,11846458,BindingDB,4-amino-5-cyano-6-ethoxy-N-methylpyridine-2-carboxamide,15911,2-pyridinecarboxamide deriv. 8a,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15911,1662,Mitogen-activated protein kinase 8,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1662,P45983,Mitogen-activated protein kinase 8,5599.0,MAPK8,9606,Homo sapiens (human),,IC50 (nM),1200,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
239,1969410,11846458,BindingDB,4-amino-5-cyano-6-ethoxy-N-methylpyridine-2-carboxamide,15911,2-pyridinecarboxamide deriv. 8a,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15911,1663,Mitogen-activated protein kinase 9,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1663,P45984,Mitogen-activated protein kinase 9,5601.0,MAPK9,9606,Homo sapiens (human),,IC50 (nM),610,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
240,1969411,11846459,BindingDB,"4-amino-5-cyano-N-(2,5-dimethoxybenzyl)-6-ethoxypyridine-2-carboxamide",15909,2-pyridinecarboxamide deriv. 3,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15909,1663,Mitogen-activated protein kinase 9,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1663,P45984,Mitogen-activated protein kinase 9,5601.0,MAPK9,9606,Homo sapiens (human),,IC50 (nM),120,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
241,1969412,11846459,BindingDB,"4-amino-5-cyano-N-(2,5-dimethoxybenzyl)-6-ethoxypyridine-2-carboxamide",15909,2-pyridinecarboxamide deriv. 3,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15909,1662,Mitogen-activated protein kinase 8,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1662,P45983,Mitogen-activated protein kinase 8,5599.0,MAPK8,9606,Homo sapiens (human),,IC50 (nM),71,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
242,1969413,11846461,BindingDB,4-amino-N-benzyl-5-cyano-6-ethoxypyridine-2-carboxamide,15912,2-pyridinecarboxamide deriv. 8b,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15912,1662,Mitogen-activated protein kinase 8,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1662,P45983,Mitogen-activated protein kinase 8,5599.0,MAPK8,9606,Homo sapiens (human),,IC50 (nM),270,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
243,1969414,11846461,BindingDB,4-amino-N-benzyl-5-cyano-6-ethoxypyridine-2-carboxamide,15912,2-pyridinecarboxamide deriv. 8b,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15912,1663,Mitogen-activated protein kinase 9,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1663,P45984,Mitogen-activated protein kinase 9,5601.0,MAPK9,9606,Homo sapiens (human),,IC50 (nM),190,PMID:16854050|DOI:10.1021/jm060465l,https://www.ncbi.nlm.nih.gov/pubmed/16854050|https://doi.org/10.1021/jm060465l,16854050.0,10.1021/jm060465l,
244,1969425,11846473,BindingDB,"tert-butyl N-[(3R,6S,9R,13Z)-3-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadec-13-en-9-yl]carbamate",16068,dithia macrocycle compound 27,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16068,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),9000,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
245,1969426,11846473,BindingDB,"tert-butyl N-[(3R,6S,9R,13Z)-3-[(1S,3R)-3-(butylcarbamoyl)-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadec-13-en-9-yl]carbamate",16068,dithia macrocycle compound 27,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16068,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),460,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
246,1969427,11846474,BindingDB,"(2R,4S)-4-[(3R,6S,9R)-9-(acetylamino)-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadecan-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",16070,"(2R,4S)-4-[(3R,6S,9R)-9-(acetylamino)-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadecan-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16070,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),9700,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
247,1969428,11846474,BindingDB,"(2R,4S)-4-[(3R,6S,9R)-9-(acetylamino)-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadecan-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",16070,"(2R,4S)-4-[(3R,6S,9R)-9-(acetylamino)-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadecan-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16070,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),>10000,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
248,1969429,11846475,BindingDB,"(2R,4S)-4-[(3R,6S,9R)-9-(acetylamino)-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclohexadecan-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",16071,"(2R,4S)-4-[(3R,6S,9R)-9-(acetylamino)-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclohexadecan-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16071,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),>10000,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
249,1969430,11846475,BindingDB,"(2R,4S)-4-[(3R,6S,9R)-9-(acetylamino)-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclohexadecan-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",16071,"(2R,4S)-4-[(3R,6S,9R)-9-(acetylamino)-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclohexadecan-3-yl]-N-butyl-4-hydroxy-2-methylbutanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16071,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),1700,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
250,1969431,11846476,BindingDB,"(2R,4S)-4-[(5R,8S,11R)-11-(acetylamino)-8-methyl-7,10-dioxo-3,13-dithia-6,9-diazabicyclo[13.2.2]nonadeca-1(17),15,18-trien-5-yl]-N-butyl-4-hydroxy-2-methylbutanamide",16073,"(2R,4S)-4-[(5R,8S,11R)-11-(acetylamino)-8-methyl-7,10-dioxo-3,13-dithia-6,9-diazabicyclo[13.2.2]nonadeca-1(17),15,18-trien-5-yl]-N-butyl-4-hydroxy-2-methylbutanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16073,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),>10000,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
251,1969452,11846476,BindingDB,"(2R,4S)-4-[(5R,8S,11R)-11-(acetylamino)-8-methyl-7,10-dioxo-3,13-dithia-6,9-diazabicyclo[13.2.2]nonadeca-1(17),15,18-trien-5-yl]-N-butyl-4-hydroxy-2-methylbutanamide",16073,"(2R,4S)-4-[(5R,8S,11R)-11-(acetylamino)-8-methyl-7,10-dioxo-3,13-dithia-6,9-diazabicyclo[13.2.2]nonadeca-1(17),15,18-trien-5-yl]-N-butyl-4-hydroxy-2-methylbutanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16073,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),3600,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
252,1969458,11846478,BindingDB,"(2R,4S)-N-butyl-4-hydroxy-2-methyl-4-[(3R,6S,13E)-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadec-13-en-3-yl]butanamide",16075,"(2R,4S)-N-butyl-4-hydroxy-2-methyl-4-[(3R,6S,13E)-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadec-13-en-3-yl]butanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16075,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),>10000,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
253,1969455,11846645,BindingDB,"tert-butyl N-[(3R,6S,9R,13Z)-3-[(1S,3R)-3-{[(1S)-1-(butylcarbamoyl)-2-methylpropyl]carbamoyl}-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadec-13-en-9-yl]carbamate",16083,cis-dithia macrocycle compound 41,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16083,1671,Beta-secretase 1 [1-453],https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1671,P56817,Beta-secretase 1,23621.0,BACE1,9606,Homo sapiens (human),,IC50 (nM),1970,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
254,1969456,11846645,BindingDB,"tert-butyl N-[(3R,6S,9R,13Z)-3-[(1S,3R)-3-{[(1S)-1-(butylcarbamoyl)-2-methylpropyl]carbamoyl}-1-hydroxy-3-methylpropyl]-6-methyl-5,8-dioxo-1,11-dithia-4,7-diazacyclopentadec-13-en-9-yl]carbamate",16083,cis-dithia macrocycle compound 41,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16083,1673,Cathepsin D,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1673,P07339,Cathepsin D,1509.0,CTSD,9606,Homo sapiens (human),,IC50 (nM),50,PMID:16854060|DOI:10.1021/jm060154a,https://www.ncbi.nlm.nih.gov/pubmed/16854060|https://doi.org/10.1021/jm060154a,16854060.0,10.1021/jm060154a,
255,1969559,15959301,BindingDB,"ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]-3-phenylpropanamido]-5-phenylpent-2-enoate",11258,AG7088 analogue 4d,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=11258,4753,Replicase polyprotein 1ab,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=4753,P0C6X7,Replicase polyprotein 1ab,1489680.0,ORF1ab,694009,Severe acute respiratory syndrome-related coronavirus,,IC50 (nM),11000,PMID:15994085|DOI:10.1016/j.bmc.2005.05.065,https://www.ncbi.nlm.nih.gov/pubmed/15994085|https://doi.org/10.1016/j.bmc.2005.05.065,15994085.0,10.1016/j.bmc.2005.05.065,
256,1969560,15959302,BindingDB,"ethyl (2E,4S)-5-phenyl-4-[(2S)-3-phenyl-2-[(2E)-3-(4-phenylphenyl)prop-2-enamido]propanamido]pent-2-enoate",11259,dipeptidomimetic unsaturated ester 18a,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=11259,4753,Replicase polyprotein 1ab,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=4753,P0C6X7,Replicase polyprotein 1ab,1489680.0,ORF1ab,694009,Severe acute respiratory syndrome-related coronavirus,,Ki (nM),6440,PMID:15994085|DOI:10.1016/j.bmc.2005.05.065,https://www.ncbi.nlm.nih.gov/pubmed/15994085|https://doi.org/10.1016/j.bmc.2005.05.065,15994085.0,10.1016/j.bmc.2005.05.065,
257,1969561,15959303,BindingDB,"ethyl (2E,4S)-4-[(2S)-2-[(2E)-3-(4-nitrophenyl)prop-2-enamido]-3-phenylpropanamido]-5-phenylpent-2-enoate",11260,dipeptidomimetic unsaturated ester 18b,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=11260,4753,Replicase polyprotein 1ab,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=4753,P0C6X7,Replicase polyprotein 1ab,1489680.0,ORF1ab,694009,Severe acute respiratory syndrome-related coronavirus,,Ki (nM),2480,PMID:15994085|DOI:10.1016/j.bmc.2005.05.065,https://www.ncbi.nlm.nih.gov/pubmed/15994085|https://doi.org/10.1016/j.bmc.2005.05.065,15994085.0,10.1016/j.bmc.2005.05.065,
258,1969562,15959304,BindingDB,"ethyl (2E,4S)-4-[(2S)-2-[(2E)-3-(2,4-dimethoxyphenyl)prop-2-enamido]-3-phenylpropanamido]-5-phenylpent-2-enoate",11262,dipeptidomimetic unsaturated ester 18d,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=11262,4753,Replicase polyprotein 1ab,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=4753,P0C6X7,Replicase polyprotein 1ab,1489680.0,ORF1ab,694009,Severe acute respiratory syndrome-related coronavirus,,Ki (nM),9049,PMID:15994085|DOI:10.1016/j.bmc.2005.05.065,https://www.ncbi.nlm.nih.gov/pubmed/15994085|https://doi.org/10.1016/j.bmc.2005.05.065,15994085.0,10.1016/j.bmc.2005.05.065,
259,1969563,15959316,BindingDB,"(2S)-N-[(1S)-1-{[(1S,2S)-1-{[(1S)-1-[(2-chloro-4-nitrophenyl)carbamoyl]-2-phenylethyl]carbamoyl}-2-hydroxypropyl]carbamoyl}-2-phenylethyl]-3-methyl-2-[(5-methyl-1,2-oxazol-3-yl)formamido]butanamide",11239,"(2S)-N-[(1S)-1-{[(1S,2S)-1-{[(1S)-1-[(2-chloro-4-nitrophenyl)carbamoyl]-2-phenylethyl]carbamoyl}-2-hydroxypropyl]carbamoyl}-2-phenylethyl]-3-methyl-2-[(5-methyl-1,2-oxazol-3-yl)formamido]butanamide",https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=11239,4753,Replicase polyprotein 1ab,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=4753,P0C6X7,Replicase polyprotein 1ab,1489680.0,ORF1ab,694009,Severe acute respiratory syndrome-related coronavirus,,Ki (nM),1610,PMID:15974598|DOI:10.1021/jm050184y,https://www.ncbi.nlm.nih.gov/pubmed/15974598|https://doi.org/10.1021/jm050184y,15974598.0,10.1021/jm050184y,
260,1969564,15959317,BindingDB,"benzyl N-[(1S)-1-{[(1S)-1-{[(1S,2S)-1-{[(1S)-1-[(2-chloro-4-nitrophenyl)carbamoyl]-2-phenylethyl]carbamoyl}-2-hydroxypropyl]carbamoyl}-2-phenylethyl]carbamoyl}-2-methylpropyl]carbamate",11240,Anilide Inhibitor 4k,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=11240,4753,Replicase polyprotein 1ab,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=4753,P0C6X7,Replicase polyprotein 1ab,1489680.0,ORF1ab,694009,Severe acute respiratory syndrome-related coronavirus,,Ki (nM),1510,PMID:15974598|DOI:10.1021/jm050184y,https://www.ncbi.nlm.nih.gov/pubmed/15974598|https://doi.org/10.1021/jm050184y,15974598.0,10.1021/jm050184y,
261,1969565,15960649,BindingDB,,231697,RR601,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=231697,9936,Dual specificity protein phosphatase 5,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=9936,Q16690,Dual specificity protein phosphatase 5,1847.0,DUSP5,9606,Homo sapiens (human),,IC50 (nM),3.69e+4,PMID:28569147|DOI:10.1186/s12858-017-0083-3,https://www.ncbi.nlm.nih.gov/pubmed/28569147|https://doi.org/10.1186/s12858-017-0083-3,28569147.0,10.1186/s12858-017-0083-3,
